argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$960.04−21.29 (-2.17%)
Close on Nov 13, 2026Market cap –P/E 49.1Yield –
argenx total assets
Total assets on the balance sheet at the end of each period.
argenx's total assets was $10.03B at Jun 30, 2026. For fiscal 2025 it was $8.68B, up 40.0% from the year before. The highest annual figure on record is $8.68B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.68B | +40.0% |
| FY2024 | Dec 31, 2024 | $6.20B | +36.5% |
| FY2023 | Dec 31, 2023 | $4.54B | +44.9% |
| FY2022 | Dec 31, 2022 | $3.13B | +10.0% |
| FY2021 | Dec 31, 2021 | $2.85B | +25.0% |
| FY2020 | Dec 31, 2020 | $2.28B | +41.6% |
| FY2019 | Dec 31, 2019 | $1.61B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.03B | +109.1% |
| Q4 FY2025 | Dec 31, 2025 | $8.68B | +91.2% |
| Q2 FY2025 | Jun 30, 2025 | $7.18B | +124.7% |
| Q4 FY2024 | Dec 31, 2024 | $6.20B | +97.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.80B | +47.6% |
| Q4 FY2023 | Dec 31, 2023 | $4.54B | +59.4% |
| Q2 FY2023 | Jun 30, 2023 | $3.19B | -0.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.13B | +37.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.25B | +101.8% |
| Q4 FY2021 | Dec 31, 2021 | $2.85B | – |
| Q2 FY2021 | Jun 30, 2021 | $3.21B | – |
| Q4 FY2020 | Dec 31, 2020 | $2.28B | – |
| Q4 FY2019 | Dec 31, 2019 | $1.61B | – |
See a number that looks wrong?